Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
JNCI Cancer Spectrum is Scopus-indexed (Q2, CiteScore 6), WoS ESCI, DOAJ. It is covered by India's One Nation One Subscription scheme, which pays the article processing charge for authors at eligible institutions. Published by Oxford University Press.
Checked against the index lists dated .
ISSN 2515-5091Verify ISSN ↗
Publisher: Oxford University Press
Cost to publish: APC covered for authors at ONOS-subscribed Indian institutions
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 111 / 428 | 74th | Q2 |
| Cancer Research | 96 / 233 | 59th | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription)
Yes — actively indexed in Scopus, coverage 2017–present, best quartile Q2, CiteScore 6.
JNCI Cancer Spectrum is Q2 in Oncology (rank 111 of 428) and Q2 in Cancer Research (rank 96 of 233), by CiteScore 2025.
JNCI Cancer Spectrum is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 6, which places it in quartile Q2 at the 74th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.720, quartile Q1, with an H-index of 46.
For authors at Indian institutions covered by One Nation One Subscription (ONOS), the article processing charge is paid by the scheme. The publisher lists an article processing charge of about US$2,050 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
JNCI Cancer Spectrum is published by Oxford University Press. Its ISSN is 2515-5091.
Yes. ONOS also covers its article processing charge for authors at eligible institutions.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
JNCI Cancer Spectrum has an h-index of 55 and a 2-year mean of 3.68 citations per paper (OpenAlex). Its Scopus CiteScore is 6, quartile Q2. On 2-year citations it ranks #87 of 424 Scopus journals in Oncology.
JNCI Cancer Spectrum published 123 papers in 2025; its busiest recent year was 2024 with 131. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2025–2026), authors are most often from United States (63.1%), Canada (5.8%) and Japan (5.7%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (2.1 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.